Updated February 2010

It is a pleasure for me to welcome you to the Fibrocell Science, Inc. web site during this pivotal period for the company and our lead investigational cell therapy, azficel-T.

After serving as Fibrocell’s Chairman of the Board since September 2009, I’m excited to now add the title of Chief Executive Officer to my role within the company. As CEO, I hope to leverage my broad leadership experience in healthcare sales and commercialization – garnered primarily through a long career at GlaxoSmithKline – to help obtain U.S. Food & Drug Administration (FDA) approval for azficel-T and to bring it to market with the support structure required to ensure it is widely available for all approved patient populations.

Our most immediate task at hand at Fibrocell is to continue to respond to the FDA’s requests as outlined in its complete response letter to our March 2009 biologics license application for azficel-T’s use in the treatment of moderate to severe nasolabial fold wrinkles. Our clinical and regulatory teams are currently in dialogue with the FDA to help determine next steps.

Beyond that, our entire organization is focusing on ways to expand the potential of regenerative fibroblast cells for additional aesthetic, medical and scientific applications. Broadly, the regenerative effects of fibroblasts in the body include the ability to improve skin texture through synthesizing the extracellular matrix components, secreting collagen and other matrix fibers, and playing a critical role in wound healing and tissue repair.

At Fibrocell, we are proud of our unique, streamlined manufacturing process. Azficel-T preparation begins when a physician removes a small sample of cells from behind a patient’s ear and sends that sample to the Fibrocell cGMP facility. The process expands fibroblasts into tens of millions of new cells, which are then formulated into an autologous cellular therapy. Cells are frozen and used for multiple treatment sessions. The therapy is reintroduced into the patient’s skin by injection, which we believe results in an increase in the local fibroblast population, collagen formation and assists the body’s own regenerative healing process.

Thank you for your interest in Fibrocell Science, Inc. Please visit our site often so that we can continue to provide you updates on our progress.

Sincerely,
David Pernock
Chairman & CEO
Fibrocell Science, Inc.